Hydronidone

Summary

Hydronidone (CHEMBL4297288) is a phase-3 clinical-stage small molecule; indicated across 3 conditions including cirrhosis of liver and chronic hepatitis b virus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 3 conditions
• Clinical trials: 14
• Chemistry: 201.22 Da · C12H11NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297288
Name	Hydronidone
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	11217901
Molecular formula	C12H11NO2
Molecular weight	201.22
InChIKey	NETTXQJYJRFTFS-UHFFFAOYSA-N

SMILES: CC1=CN(C(=O)C=C1)C2=CC=C(C=C2)O

IUPAC name: 1-(4-hydroxyphenyl)-5-methylpyridin-2-one

Also known as: F 351, F-351, Hydronidone, HYDRONIDONE, F351

Patent coverage: 63 distinct patent families (184 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cirrhosis of liver	3	MONDO:0005155	EFO:0001422
chronic hepatitis B virus infection	2	MONDO:0005366	EFO:0004239
liver disorder	1	MONDO:0005154	HP:0001410

Clinical trials

Total trials: 14.

Phase distribution

Phase	Trials
PHASE1	7
PHASE3	4
PHASE2	3

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05905172	PHASE3	RECRUITING	Hydronidone Capsules in Long-term Treatment in Patients With Chronic Viral Hepatitis B Liver Fibrosis
NCT07343778	PHASE3	RECRUITING	A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis
NCT07412236	PHASE3	NOT_YET_RECRUITING	A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.
NCT05115942	PHASE3	COMPLETED	Hydronidone for the Treatment of Liver Fibrosis Associated with Chronic Viral Hepatitis B Phase 3 Trial.
NCT07364448	PHASE2	RECRUITING	A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis
NCT07417553	PHASE2	RECRUITING	A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis
NCT02499562	PHASE2	COMPLETED	A Phase II Clinical Trial of Hydronidone Capsules(F351) in Patients With Liver Fibrosis Induced by HBV Chronic Hepatitis
NCT07262333	PHASE1	RECRUITING	A Trial of Hydroxynidone Capsules in Single-dose Administration for Patients With Renal Insufficiency
NCT07262346	PHASE1	NOT_YET_RECRUITING	The Phase Ⅰd Clinical Trial of Hydronidone Capsules
NCT07394309	PHASE1	NOT_YET_RECRUITING	Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls
NCT04123769	PHASE1	COMPLETED	Study on PK of Hydronidone in Patients and Special Population
NCT04124081	PHASE1	COMPLETED	Pharmacokinetic Interactions Between Hydronidone and Entecavir Capsules in Healthy Chinese Subjects
NCT04162821	PHASE1	COMPLETED	Study on Pharmacokinetics of Hydronidone
NCT07263152	PHASE1	COMPLETED	QTc Assessment in a Single-Dose Study of Hydronidone Capsules

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).